Overview
This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.
Eligibility
Inclusion Criteria:
- Pregnant individuals receiving prenatal care at participating clinics
- \<12 weeks gestation with a viable intrauterine pregnancy
- Age ≥18 years
- English-speaking
Exclusion Criteria:
- Unable or unwilling to self-administer vaginal progesterone
- Inability or unwillingness to provide informed consent
